Impact of arsenic trioxide on LS-174T cell growth in vitro and the activity of telomerase

被引:1
作者
Wang, XS
Wang, GY
Xu, HT
Dong, DL
Fu, SB
Zhang, QF
Yang, BF
机构
[1] Harbin Med Coll, Dept Pharmacol, Harbin 150001, Peoples R China
[2] Harbin Med Coll, Dept Genet, Harbin 150001, Peoples R China
关键词
arsenic trioxide; telomerase; colorectal carcinoma; apoptosis;
D O I
10.1016/S1005-9040(06)60078-0
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The therapeutic action of arsenic trioxide (As2O3) on solid tumors has aroused widespread interest among scholars. To study the impact of As2O3, on human colorectal carcinoma cells(LS-1.74T cell) and the activity of telomerase, the methods of PCR-ELISA, flow cytometry (FCM) and MTT assay in vitro were utilized. The results show that (1) with an increase in the concentration of As2O3, the ratio of living the cells to dead cells decreases significantly, and the IC50 value is 5.23 mu g/mL; (2) the cells of the experimental groups can endure a series of morphological changes similar to the features of apoptosis; (3) the apoptotic curves of FCM pictures appear after 24 h, and the cells show the apoptosis in a time-dependent manner; (4) As2O3 can inhibit the activity of telomerase of the cell extraction obviously in a concentration-dependent and time-dependent manner after 24 h. It can be concluded from the experiment results in vitro that As2O3 can induce the apoptosis of LS-174T cells and inhibit the telomerase activity. Therefore, it has been proposed, for the first time, that these two factors( the apoptosis of LS-174T cells and the inhibition to the telomerase activity) are important causes of the LS-174T cell death caused by As2O3.
引用
收藏
页码:209 / 212
页数:4
相关论文
共 17 条
  • [1] Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells
    Baumgartner, M
    Sturlan, S
    Roth, E
    Wessner, B
    Bachleitner-Hofmann, T
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (04) : 707 - 712
  • [2] Chen GQ, 1997, BLOOD, V89, P3345
  • [3] Chen GQ, 1996, BLOOD, V88, P1052
  • [4] Du CW, 2004, NATL MED J INDIA, V17, P67
  • [5] The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future
    Evens, AM
    Tallman, MS
    Gartenhaus, RB
    [J]. LEUKEMIA RESEARCH, 2004, 28 (09) : 891 - 900
  • [6] Jiang GS, 2003, CHINESE MED J-PEKING, V116, P1639
  • [7] Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53
    Karlsson, J
    Ora, I
    Pörn-Ares, I
    Påhlman, S
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (09) : 3179 - 3188
  • [8] LI X, 2004, CANC INVEST, V22, P189
  • [9] Acute promyelocytic leukemia: evolving therapeutic strategies
    Tallman, MS
    Nabhan, C
    Feusner, JH
    Rowe, JM
    [J]. BLOOD, 2002, 99 (03) : 759 - 767
  • [10] TALLMANN MS, 2004, ANN HEMATOL, V83, P81